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Haemostatic therapy for trauma-induced coagulopathy is 
typically based on administration of allogeneic blood 
products, although the evidence supporting this approach 
is poor [1]. Fixed-ratio protocols have been proposed for 
administering fresh frozen plasma, red blood cells and 
platelets, but the optimal ratio has not been established 
and the speed of intervention may be more important [2].
In contrast to ﬁ xed-ratio treatment, coagulation factor 
concentrate therapy guided by point-of-care monitoring 
allows patients’ actual needs to be targeted [3]. Our initial 
experience with ROTEM® (Tem International GmbH, 
Munich, Germany) indicated correlation between the 
clinical condition and extent of coagulo pathy, suggesting 
a need for the early identiﬁ cation and treatment of 
coagulopathy that ROTEM® enables. Altogether, these 
factors provided a rationale for imple menting ROTEM®-
guided therapy for trauma patients in our hospital.
In our experience, this approach is feasible and can 
replace formula-driven treatment. We found that coagu-
lation factor concentrates (ﬁ brinogen concentrate and 
prothrombin complex concentrate) correct coagulopathy 
eﬀ ectively and rapidly, indicated by normalisation of 
ROTEM® parameters among bleeding trauma patients 
(Table  1). European guidelines for managing trauma 
raised the target ﬁ brinogen concentra tion to 1.5 to 2 g/l 
[4], which we ﬁ nd diﬃ  cult to reach without using 
ﬁ brinogen concentrate. Without a com parator group, our 
data are insuﬃ  cient to show reduced red blood cell 
transfusion or improvements in morbidity/mortality. 
However, we did see a progressive reduction in fresh 
frozen plasma consumption. Another advantage of using 
a ROTEM®-guided approach is the opportunity to detect 
hyperﬁ brinolysis. As reported elsewhere, we found that 
fulminant hyperﬁ brinolysis is associated with high 
mortality. Fulminant hyperﬁ brinolysis may potentially be 
considered the last gasp of the coagulation system; it may 
be a marker not only of severe coagulopathy, but also of 
poor clinical outcome. Our experience also suggests that 
patients with massive bleeding may beneﬁ t from imme-
diate, proactive administration of 1  g tranexamic acid 
followed by 2 to 4 g ﬁ brinogen concentrate, with further 
doses as soon as ROTEM® results are available.
Fibrinogen concentrate is currently imported in Italy 
and we use it according to the manufacturer’s label. In 
some countries the product is licensed only for congenital 
deﬁ ciency. However, it is possible to use life-saving drugs 
for indications beyond the label, providing the physician 
is convinced that this use is in the patient’s best interest; 
such practice is regulated by health authorities in several 
countries. High-quality, randomised controlled trials are 
lacking for both allogeneics and coagulation factor 
concen trates in trauma, creating a degree of uncertainty 
with both of these options. Nevertheless, we consider the 
rationale to be stronger for ROTEM®-guided, concentrate-
based therapy.
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